Mirati Therapeutics Inc. (MRTX) Receives $22.77 Consensus Target Price from Analysts
Shares of Mirati Therapeutics Inc. (NASDAQ:MRTX) have received a consensus recommendation of “Buy” from the ten brokerages that are covering the firm. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $22.77.
Several equities analysts have recently commented on MRTX shares. Zacks Investment Research upgraded shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 6th. Wedbush restated an “outperform” rating and set a $12.00 price target on shares of Mirati Therapeutics in a report on Tuesday, October 4th. Finally, Piper Jaffray Cos. restated a “neutral” rating on shares of Mirati Therapeutics in a report on Friday, August 19th.
Several large investors have recently added to or reduced their stakes in the stock. Aviva Holdings Ltd. raised its stake in Mirati Therapeutics by 195.9% in the first quarter. Aviva Holdings Ltd. now owns 1,546,001 shares of the company’s stock valued at $33,328,000 after buying an additional 1,023,501 shares during the last quarter. venBio Select Advisor LLC raised its stake in Mirati Therapeutics by 11.6% in the first quarter. venBio Select Advisor LLC now owns 1,404,055 shares of the company’s stock valued at $30,047,000 after buying an additional 146,000 shares during the last quarter. Macquarie Group Ltd. acquired a new stake in Mirati Therapeutics during the second quarter valued at about $437,000. Sabby Management LLC raised its stake in Mirati Therapeutics by 116.7% in the first quarter. Sabby Management LLC now owns 56,400 shares of the company’s stock valued at $1,207,000 after buying an additional 30,373 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in Mirati Therapeutics by 24.8% in the first quarter. Royal Bank of Canada now owns 19,250 shares of the company’s stock valued at $412,000 after buying an additional 3,828 shares during the last quarter. 69.40% of the stock is owned by institutional investors and hedge funds.
Shares of Mirati Therapeutics (NASDAQ:MRTX) opened at 5.24 on Friday. The firm’s market capitalization is $104.40 million. Mirati Therapeutics has a 52 week low of $4.40 and a 52 week high of $43.20. The stock’s 50 day moving average price is $5.57 and its 200 day moving average price is $10.51.
Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.04. On average, analysts predict that Mirati Therapeutics will post ($4.45) EPS for the current fiscal year.
About Mirati Therapeutics
Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.